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Abstract
This review focuses on the complex events that occur in the endometrium after progesterone is
withdrawn (or blocked) and menstrual bleeding ensues. A detailed understanding of these local
mechanisms will enhance our knowledge of disturbed endometrial/uterine function – including
problems with excessively heavy menstrual bleeding, endometriosis and breakthrough bleeding
with progestin only contraception. The development of novel strategies to manage these clinically
significant problems depends on such new understanding as does the development of new
contraceptives which avoid the endometrial side effect of breakthrough bleeding.
Introduction
The uterus plays a pivotal role in the key events of primate
reproduction, implantation, and in the absence of preg-
nancy, menstruation. Preparation of the endometrium for
implantation is a consequence of exposure of this steroid
target tissue to estradiol and progesterone [1,2]. Absence
of pregnancy, demise of the corpus luteum and the subse-
quent fall in circulating progesterone leads to degradation
and shedding of the superficial layer of the endometrium.
Menstruation is a process of tissue injury and subsequent
repair involving a complex interplay between the endo-
crine and local immune system [3,4]. It is well known that
progesterone is the steroid critical for endometrial differ-
entiation, but the specific determinants of endometrial
receptivity and the complex molecular and cellular inter-
actions involved are matters of current research. Modern,
post-genomic technologies are being used to advance our
knowledge of the complex events of implantation and
menstruation [5-9].
Repetitive episodes of menstrual bleeding are the outward
indicators of cyclical ovarian function. In the past, when
contraception was not available or widely practiced large
family sizes were associated with long periods of lactation
which in turn suppressed ovulation and induced amenor-
rhea. As a consequence, women's lives were practically
menstruation free [10,11]. Nowadays, because contracep-
tion is more widely practiced in developed societies,
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their reproductive lifespan. Disorders of the menstrual
process are therefore one of the banes of modern women.
The following review focuses on the complex events that
occur in the endometrium after progesterone is with-
drawn (or blocked) and menstrual bleeding ensues. A
detailed understanding of these local mechanisms will
enhance our knowledge of disturbed endometrial/uterine
function – including problems with excessively heavy
menstrual bleeding, endometriosis, and breakthrough
bleeding with progestin only contraception. The develop-
ment of novel strategies to manage these clinically signif-
icant problems depends on such new understanding as
does the development of new contraceptives which avoid
the endometrial side effect of breakthrough bleeding.
Endometrial sex steroid receptor expression
1. Endometrial progesterone receptor (PR) expression
Steroid hormones are the systemic factors that drive the
endometrium through the characteristic sequential
phases of the menstrual cycle [12]. Steroids interact with
their target cells via specific nuclear receptors with conse-
quential initiation of gene transcription and a cascade of
downstream molecular and cellular events. Members of
the nuclear receptor super-family expressed by endome-
trial cells include progestin, estrogen, androgen and glu-
cocorticoid receptors. Estrogen receptor (ER) and
progesterone receptor (PR) expression is under dual con-
trol of estradiol and progesterone, and along with the
androgen receptor (AR) varies both temporally and spa-
tially across the menstrual cycle [13-17].
Two isoforms of the human PR have been described
[18,19]. PRA is the shorter isoform, missing 164 amino
acids at the end terminus of the B subtype. PRA and PRB
derive from a single gene and function as transcriptional
regulators of progestin-responsive genes. There is a signif-
icant decline in PR expression in the glands of the func-
tional layer of the endometrium with the transition from
the proliferative to the secretory phase of the cycle. PR per-
sists in the stroma in the upper functional zone, and is
particularly highly expressed in the stromal cells in close
proximity to the uterine vasculature. The basal region is
regulated differently in that the glands and stroma of the
deeper zones express PR throughout the cycle. Localisa-
tion studies utilising antibodies that recognise both PR
isoforms have shown that PR is also differentially regu-
lated in stromal versus epithelial cells. For example, in the
secretory phase the PRB isoform declines in the stroma
and PRA becomes the dominant form, while both forms
decline in the epithelial cells of the functional layer
[20,21]. The differential expression of the PR in the super-
ficial and basal regions of the endometrium is likely to
have functional importance because only the superficial
layers are shed during menstruation.
The progesterone receptor has been described as being
present in blood vessel walls but absent from the vascular
endothelium of the human uterus [16,22]. In the rhesus
macaque endometrium, PR is absent from both the
endothelial cells of capillaries and the smooth muscle
cells of the artery walls but is strongly expressed in the
perivascular stroma, which is closely apposed to the mus-
cular wall [23]. Therefore, the effects of progesterone or
progesterone withdrawal on vasoconstriction and
endometrial bleeding are likely to be indirect effects,
mediated by the PR-positive perivascular stromal cells.
2. Endometrial ER expression
Several of the fundamental processes involved in normal
endometrial function, such as proliferation [24] and vas-
cularization [25] are regulated by estrogen. Estrogen
upregulates key endometrial genes including PR, vascular
endothelial growth factor (VEGF), and lactoferrin [26-28].
Upregulation of PR in the proliferative phase is consistent
with identification of estrogen response elements in the
regulatory region of the PR gene [29] thus providing evi-
dence for a functional estrogen mediated pathway in the
proliferative phase. VEGF is a key local mediator of cycli-
cal neovascularisation in the functional layer and VEGF
mRNA increases in the mid proliferative phase [30].
Estrogen action is mediated by two variants of estrogen
receptor referred to as ERα and ERβ [16,31-33]. The func-
tion of ERβ in the uterus is still to be determined. In the
upper functional layer, ERα expression increases in both
glandular and stromal cells in the proliferative phase and
declines in the secretory phase due to suppression by pro-
gesterone. In the basal layer, ERα is expressed in glandular
and stromal cells throughout the menstrual cycle in
women [13,15] and nonhuman primates [34].
In human and non human primate endometrium
[16,22,35,36], ERβ was the only sex steroid receptor that
was present in the endothelium and smooth muscle walls
of endometrial vessels. ERα, PR, and AR were not detecta-
ble in either the endothelium or vascular smooth muscle
cells of primate endometrial vessels but were strongly
expressed in the perivascular stroma where they were
increased by estrogen and suppressed by progesterone in
the functional layer. We concluded that any direct effects
of estrogen on endometrial vessels, including angiogen-
esis and permeability, would be mediated by ER β, and
that the actions of progestins and androgens would be
mediated indirectly by perivascular stromal cells.
In vitro studies have demonstrated that homodimers
(ERα- ERα or ERβ-ERβ) or heterodimers (ERα- ERβ) canPage 2 of 9
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cell [37,38]. When tested in vitro on a luciferase reporter
gene linked to an estrogen response element and activated
with estradiol or diethylstilbestrol, both receptor
homodimers induce similar trans-activation profiles, but
they signal in opposite ways at an activating protein-1 site
[39]. Studies reported by Hall and McDonnell [40] have
indicated that one role played by ERβ may be to modulate
ERα transcriptional activity. A novel human ERβ variant
named hERβcx (ERβcx/β2) formed by alternative splicing
of the eighth exon of ERβ (ERβ1) has been identified [41].
Thus the structure of an estrogenic ligand, its concentra-
tion, the presence of co-regulators, and the subtype(s) of
ER expressed in each cell will determine the pattern of
estrogen-induced gene expression [42]. The cellular distri-
butions of ERβ1 and ERβcx/β2 variants may have impor-
tant implications for the regulation of implantation and
menstruation, and also for dysfunctional aspects of these
events. It has been reported that mRNAs corresponding to
both ERβ1 and ERβcx/β2 variants were detectable in
human endometrial tissue [36]. ERβcx/β2 variant was
detected with a semi-quantitative PCR approach in all
endometrial tissue samples regardless of the stage of the
cycle. ERβ1 and ERβcx/β2 proteins were localized to mul-
tiple cell types within the endometrium through the use
of isoform-specific monoclonal antibodies; immunoex-
pression of ERβ1 appeared more intense than that of
ERβcx/β2 in endometrial epithelium and endothelial
cells. Immunoexpression of ERβ1 appeared unchanged
throughout the menstrual cycle. In contrast, levels of
ERβcx/β2-specific immunoreactivity were specifically
reduced in gland cells within the functional layer, but not
in those of the basal layer, in the mid-secretory phase.
Therefore, co-expression of ERβcx/β2 in cells containing
ERβ1 and/or ERα could modulate the effects of estrogens
on the endometrium [36].
3. Endometrial androgen receptor (AR) expression
Exogenous androgen administration has an inhibitory
effect on the human and non-human primate
endometrium, and can induce endometrial atrophy. Ele-
vated levels of circulating endogenous androgen have
been described in a sub group of women with recurrent
miscarriage implicating an antagonistic role for andro-
gens on endometrial estrogen effects [43]. It has been
demonstrated that androgens can suppress estrogen and
progestin receptors in the reproductive tract of estrogen-
treated, ovariectomized macaques [44]. Androgen recep-
tor expression in human and non-human primate
endometrium has been described [17,45]. In the
macaque, ligand binding, immunohistochemistry (IHC)
and in situ hybridisation (ISH) were used to demonstrate
the regulation and localisation of AR during the hormo-
nally regulated cycle. In women, endometrial androgen
receptor expression was studied by IHC, ISH, and quanti-
tative RT-PCR (Q-RT-PCR). During the normal cycle, in
both women and macaques, stromal cells are the predom-
inant cell type that express the AR. Androgen effects in the
endometrium are thus likely mediated by the stroma. Fur-
ther, endometrial AR levels are augmented by estradiol
and suppressed by progesterone. Most interestingly, anti-
progestin administration to either women or macaques
enhances AR expression in the stroma and induces AR
expression in the glands of the endometrium [17,46].
The physiological role of endometrial AR is yet to be
determined. Androgens are known to suppress estrogen-
dependent endometrial proliferation, and it has been sug-
ested [47,48] that the endometrial AR mediates the anti-
proliferative effects induced by anti-progestins. Further-
more, in the rhesus macaque, administration of the anti-
androgen, flutamide, has been shown to counteract the
suppressive effects produced by anti-progestins on
endometrial thickness, stromal compaction and mitotic
index [49]. In women and non-human primates, treat-
ment with progesterone-antagonists suppresses estrogen-
dependent mitotic activity in the endometrial glands. This
anti-proliferative effect is paradoxical, because progester-
one antagonists do not bind to the estrogen receptor.
While this phenomenon has been termed a "functional
noncompetitive antiestrogenic effect" [50] it does not
occur in all species or in all regions of the primate repro-
ductive tract, and hence is best referred to as an "endome-
trial antiproliferative effect" [48]. The endometrial
androgen receptor may be a critical component of the
mechanism by which anti-progestins suppress endome-
trial proliferation in the presence of circulating estrogens
[48].
4. Endometrial intracrinology
In human endometrium, steroidal regulation of receptor
action depends on ligand availability. The 17βHSD
enzyme family comprises eight members, of which six
human isoforms have been characterised. The primary
role of 17βHSD type2 is the conversion of estradiol to
estrone as well as testosterone to androstenedione, but in
addition it converts the inactive 20α-dihydroprogesterone
to active progesterone [51,52]. There is good evidence that
progesterone upregulates 17βHSD2 during the secretory
phase [53,54] in the endometrial glandular epithelium
[55]. Its activity decreases when progesterone concentra-
tions decrease (as with luteal regression) or after anti-pro-
gestin administration [54,55].
Levonorgestrel (LNG) is a synthetic progestin that binds
to both the AR and PR [56,57] and can increase the expres-
sion of 17βHSD2 protein, but this effect diminishes over
time. For example, administration of LNG locally, by
insertion of an intrauterine delivery system (IUS) in
women, induced a dramatic transformation of thePage 3 of 9
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followed by slow atrophy over the long term [58-60].
There were high levels of endometrial 17βHSD2 protein
identified in the first month after insertion of the LNG-
IUS accompanied by high levels of 17βHSD2 mRNA for
three months post insertion. After 3 months of treatment
there was a decrease in 17βHSD2 protein in glandular epi-
thelium and in total 17βHSD2 mRNA that persisted for
up to 12 months. These shifts were associated with a
down regulation of the PR over the same time frame [45].
Since 17βHSD2 converts estradiol to the less potent estro-
gen, estrone, the endometrial glands are exposed to more
estrone than estradiol during the first 3 months after LNG-
IUS insertion when the enzyme is elevated. Any estradiol-
dependent products of the glands that have paracrine
actions throughout the endometrium would thus be sup-
pressed. It is during the first months after LNG-IUS inser-
tion that a proportion of users report unscheduled
breakthrough bleeding (BTB). We propose that the
unscheduled BTB reported may be due in part to an intra-
cellular "functional estrogen deficiency" caused by the ele-
vated levels of 17βHSD2 that either directly or indirectly
leads to vascular fragility. 17βHSD2 protein expression is
significantly reduced following 3 months treatment, coin-
cident with the onset in improvement in menstrual bleed-
ing patterns. 17βHSD2 mRNA expression also declines,
but this occurs more slowly, becoming undetectable after
6 months of LNG-IUS treatment. One way to control this
pattern of BTB in women wearing an LNG-IUS may be to
treat them intermittently with a progesterone antagonist.
These compounds would increase endometrial estrogen
receptor levels and lower 17βHSD2 expression thereby
reversing any intracellular estrogen deficiency. Figure 1
summarizes our working hypothesis of a "functional
estrogen deficiency" and illustrates the potential of inter-
mittent treatment with progesterone antagonists to sup-
press BTB.
5. Progesterone withdrawal and up regulation of matrix 
metalloproteinases (MMPs) and the VEGF receptor type 2 (kinase 
domain receptor -KDR)
During the secretory phase, the expression and activity of
MMPs in endometrial stromal/decidual cells are inhibited
by the circulating levels of progesterone. Sex steroid with-
drawal at the end of the cycle reverses the inhibition of
many MMPs, including MMP-1, which can degrade the
interstitial collagens of the extracellular matrix (ECM) sur-
rounding pre-decidual cells, especially in the superficial
endometrium. The increase and activation of MMPs are
considered key elements of the menstruation process [61-
63]. There is also evidence that the focal expression of
MMPs within peri-menstrual and menstrual
endometrium involves local regulatory factors. Leuko-
cytes can directly release MMPs and there are important
interactions between endometrial leucocytes, stromal and
epithelial cells which result in induction and activation of
MMPs [64].
Data from rhesus macaques that have been treated with
estradiol and progesterone indicate that the induction of
menstruation and up-regulation of various MMPs is iden-
tical when either progesterone is withdrawn and estradiol
is maintained, or when both estradiol and progesterone
are withdrawn [2,65]. Moreover, the administration of the
anti-progestin mifepristone (RU 486), during the mid
secretory phase, is associated with marked endometrial
ECM breakdown and excessive menstrual bleeding
[66,67]. MMP-2 is one of the putative menstrual protein-
ases and there is evidence that stromal cell derived MMP-
2 increases just before menstruation and participates in
the breakdown of ECM. In vitro data clearly show that
progesterone withdrawal up-regulates MMP-2 [68]. In
summary, it is the withdrawal of progesterone, not estro-
gen, that is the essential signal which initiates upregula-
tion of the MMPs, even though both steroids decline
together at the demise of the corpus luteum.
Many other factors are also operative during the pre-men-
strual phase [69-71]. For example, the VEGF receptor type
2 (KDR) is expressed primarily by vascular endothelium
and only rarely in other cell types. However, KDR is dra-
matically up-regulated in the stromal cells of the superfi-
cial endometrial zones during the pre-menstrual phase in
both human and macaque endometrium [72]. The up-
regulation of stromal KDR follows progesterone with-
drawal in both women and macaques, and adding back
progesterone 24 hours after progesterone withdrawal in
the macaque interrupted stromal, but not vascular,
endothelial KDR expression. ProMMP-1 is also up-regu-
lated in a coordinate manner in the same stromal cell
population by progesterone withdrawal. Increases in
endometrial vascular endothelial growth factor (VEGF)
occur in the premenstrual phase, and, as discussed below,
this factor may play a role through KDR in endometrial
MMP expression and activation.
6. Effects of vasoconstriction and presumed hypoxia
Transplantation of explants of endometrium to the ante-
rior chamber of the eye of the rhesus macaque allowed
Markee [1] to demonstrate that vasoconstriction of the
spiral arteries was induced by the withdrawal of progester-
one. The constriction of spiral arteries was associated with
the regression of stromal tissue and onset of degradation
of the ECM [1]. Hence progesterone withdrawal not only
involves an up-regulation of inflammatory mediators as
described above but also a constriction of the spiral arter-
ies with consequent hypoxia in the zones closest to the
uterine lumen. The precise nature of the endometrial
vasoconstrictor involved has yet to be established. Candi-Page 4 of 9
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agents, such as endothelins and angiotensin II. Differ-
ences in the ratio of the endothelin receptors (ETA and
ETB) mRNA levels have been reported across the men-
strual cycle. The functional relevance of these observa-
tions is however unknown [73]. Cyclical changes of
angiotensin II and the endometrial expression of the angi-
otensin receptor subtypes implicate a role in the control of
the uterine vasculature [74].
Two phases of menstruation have been proposed [75].
The early events involved in the onset of menstruation, are
vasoconstriction and local cytokine changes, initiated by
progesterone withdrawal and are likely to be reversible.
The subsequent events however, which include the activa-
tion of lytic mechanisms are inevitable, implying that this
latter phase is progesterone independent and involves
cells which may not express PR such as uterine leukocytes
and epithelial cells. In support of this proposal, progester-
Endometrial changes after insertion of an LNG-IUS; the effects of intermittent antiprogestin therapy on bleeding.  A working hyp th sis.Figure 1
Endometrial changes after insertion of an LNG-IUS; the effects of intermittent antiprogestin therapy on 
bleeding. A working hypothesis. A Insertion of an LNG-IUS induces a process of decidualisation (grey colour) in the 
endometrium. During the first 3 months bleeding is high then slowly improves. During this time, 17βHSD-2 is elevated and 
therefore estrone, E1 (a less potent estrogen) is high and estradiol, E2 (the more potent estrogen) is low; steroid receptors are 
suppressed. After 6 months, when decidualisation is extensive, bleeding is reduced, 17βHSD-2 is low, E2 is high and E1 is low. 
Steroid receptors remain low, (though ERβ is likely to be present in the vascular endothelium). This balance of steroids at 6 
months is associated with reduced bleeding. B. Intermittent antiprogestin treatment during the first 3 months will suppress 
17βHSD-2 and thereby lower E1, elevate the more potent E2and elevate steroid receptors. This balance of steroids is similar to 
the balance at 6 months, but would allow E2 to interact with higher levels of receptors in all cell types and should suppress 
BTB. In addition, the spiral arteries would be strongly inhibited by antiprogestins, which should also suppress BTB. This peri-
odic "putting on the brakes" on bleeding may help women through the most difficult period of adjustment to an LNG-IUS, after 
which antiprogestin treatment could be stopped.Page 5 of 9
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one withdrawal prevented menstruation, while
progesterone "add back" after 36 hours failed to prevent
menses. This observation is expanded in the companion
paper in this symposium (Slayden and Brenner) that
defines a "critical period" of progesterone withdrawal in
the rhesus monkey [76]. This observation is consistent
with the view that only the early events, which occur in
PR-positive cells, may be inhibited by progesterone "add
back".
Amongst the local mediators stimulated by hypoxia,
VEGF is a prominent angiogenic factor in the human
endometrium [77]. Hypoxia up-regulates VEGF transcrip-
tion and the VEGF promoter has the response element for
hypoxia inducible factor [78,79]. The KDR promoter
however lacks the response element for hypoxia inducible
factor and hypoxia is therefore unlikely to directly up-reg-
ulate KDR. VEGF does however directly up-regulate KDR
in vascular endothelium in cerebral brain cultures [80].
There is evidence that experimental hypoxia increases lev-
els of VEGF in non-decidualised and decidualised
endometrial stromal cells. Interestingly cAMP, which
increases levels of VEGF in endometrial cells, has an addi-
tive effect on VEGF production in the presence of hypoxia
[81].
Therefore, VEGF, KDR and MMPs are co-ordinately
expressed by stromal cells in the upper functional layers of
premenstrual stage endometrium at the time of progester-
one withdrawal. Since there is evidence that VEGF can
upregulate MMPs [82,83], we concluded that a VEGF-
KDR-MMP link might be a component of the premen-
strual/menstrual process [3].
Our working hypothesis of menstrual induction is repre-
sented in figure 2; [reproduced from Critchley et al 2001
[3], with permission]. With the demise of the corpus
luteum, progesterone levels decline. The consequence of
progesterone withdrawal, in cells that contain progester-
Coincident events of progesterone withdrawal and hypoxia.Figure 2
Coincident events of progesterone withdrawal and hypoxia. Progesterone withdrawal results in an up-regulation of 
inflammatory mediators, production of MMPs, a leukocyte influx and expression of stromal KDR in the upper endometrial 
zones. There is coincident hypoxia and an up-regulation of VEGF. VEGF binds to its type 2 receptor, KDR and there is a para-
crine/autocrine action on the up-regulation of MMP production in the same endometrial upper zone stromal cells. Menstrual 
sloughing takes place from the superficial regions of the endometrium. Reproduced with permission.Page 6 of 9
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produced prostaglandins are elevated. These early events
in the menstrual process lead to vasoconstriction and
cytokine up-regulation. Coincidental constriction of the
spiral arteries results in the uppermost endometrial layer
becoming hypoxic and the distal zones ischemic. Distal
ischemia/hypoxia induces VEGF and VEGF may induce its
own receptor KDR within the stromal cells of the upper-
most layers. VEGF is able to interact with its receptor KDR
and augment, in either a paracrine or autocrine manner,
MMP expression by stromal cells. The inflammatory
mediators induce a large influx of leukocytes. The com-
bined increase in proteolytic enzymes produced first by
stromal cells and later by leukocytic cells results in the
characteristic tissue destruction and bleeding associated
with menstruation [3,84].
The complexity inherent in the cascading network of men-
strual interacting factors means that extensive research is
still needed to understand the molecular and cellular
processes underlying and controlling these events. Hope-
fully, as our knowledge increases, we will one day be able
to alleviate the severe bleeding problems so many women
endure.
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